Harvard Bioscience Inc. (HBIO) Financial Statements (2025 and earlier)

Company Profile

Business Address 84 OCTOBER HILL RD
HOLLISTON, MA 01746
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,2834,5087,8218,3178,3358,173
Cash and cash equivalent4,2834,5087,8218,3178,3358,173
Receivables16,09916,70521,83417,76620,70421,463
Inventory, net of allowances, customer advances and progress billings24,71626,43927,58722,26222,06125,087
Inventory24,71626,43927,58722,26222,06125,087
Other current assets3,9403,4724,3413,3552,4723,109
Total current assets:49,03851,12461,58351,70053,57257,832
Noncurrent Assets
Operating lease, right-of-use asset4,7735,8166,8977,7618,463
Property, plant and equipment3,9813,3663,4153,9604,7765,898
Intangible assets, net (including goodwill)73,10177,27485,07491,74195,786103,068
Goodwill57,06556,26057,68958,59057,38157,304
Intangible assets, net (excluding goodwill)16,03621,01427,38533,15138,40545,764
Other noncurrent assets6,4737,7805,3751,0922,2731,604
Other undisclosed noncurrent assets      211
Total noncurrent assets:88,32894,236100,761104,554111,298110,781
TOTAL ASSETS:137,366145,360162,344156,254164,870168,613
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,5546,4474,9115,9725,94814,099
Taxes payable  609978
Accounts payable5,5546,4474,9115,9725,3397,359
Accrued liabilities      5,762
Deferred revenue4,5083,3704,2663,7713,949
Debt 6,1394,0913,5152,0002,4244,399
Other liabilities9,2057,48610,7627,4786,0911,588
Other undisclosed current liabilities1,1361,8551,8621,8326,9001,420
Total current liabilities:26,54223,24925,31621,05325,31221,506
Noncurrent Liabilities
Long-term debt and lease obligation 30,70443,01351,58353,76755,14158,796
Long-term debt, excluding current maturities 30,70443,01345,09546,28646,91758,796
Liabilities, other than long-term debt7,0466,8782,0444,7532,7235,587
Accounts payable and accrued liabilities      3,286
Deferred tax liabilities, net2,301
Deferred income tax liabilities7765901,5581,8991,974
Other liabilities1,4761,0064862,854749 
Operating lease, liability4,7945,2826,4887,4818,224
Total noncurrent liabilities:37,75049,89153,62758,52057,86464,383
Total liabilities:64,29273,14078,94379,57383,17685,889
Equity
Equity, attributable to parent, including:73,07472,22083,40176,68181,69482,724
Common stock434454452444438436
Additional paid in capital232,435229,008225,650232,357229,189226,377
Accumulated other comprehensive loss(14,190)(15,052)(10,027)(13,066)(12,689)(13,532)
Accumulated deficit(145,605)(142,190)(132,674)(132,386)(124,576)(119,889)
Other undisclosed equity, attributable to parent    (10,668)(10,668)(10,668)
Total equity:73,07472,22083,40176,68181,69482,724
TOTAL LIABILITIES AND EQUITY:137,366145,360162,344156,254164,870168,613

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues112,250113,335118,904102,100116,176120,774
Cost of revenue
(Cost of Product and Service Sold)
(46,179)(52,516)(51,252)(44,059)(51,854)(57,593)
Gross profit:66,07160,81967,65258,04164,32263,181
Operating expenses(64,177)(67,752)(65,586)(57,820)(63,945)(62,197)
Operating income (loss):1,894(6,933)2,066221377984
Nonoperating expense(4,450)(2,246)(2,206)(7,513)(5,879)(8,959)
Other nonoperating income (expense)(227)302(666)(806)(469)(3,740)
Interest and debt expense    (393)(385)(5,367)
Other undisclosed income from continuing operations before equity method investments, income taxes    3933855,367
Loss from continuing operations before income taxes:(2,556)(9,179)(140)(7,292)(5,502)(7,975)
Income tax expense (benefit)(859)(337)(148)(518)8153,676
Loss from continuing operations:(3,415)(9,516)(288)(7,810)(4,687)(4,299)
Loss before gain (loss) on sale of properties:(288)(7,810)(4,687)(2,922)
Income from discontinued operations      1,377
Net loss available to common stockholders, diluted:(3,415)(9,516)(288)(7,810)(4,687)(2,922)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(3,415)(9,516)(288)(7,810)(4,687)(2,922)
Other comprehensive income (loss)862(5,025)3,039(377)843(2,856)
Comprehensive income (loss), net of tax, attributable to parent:(2,553)(14,541)2,751(8,187)(3,844)(5,778)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: